Drawing on years of experience studying non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), SMC has created the world’s first preclinical model with a type 2 diabetic ...
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...
In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...
Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...
One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...
Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...
Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback